Thirona, a Nijmegen-based business that uses artificial intelligence (AI) to analyze thoracic CT scans, said on Monday that it had raised €7.5 million in a new investment round.
Along with a €2.5 million grant from the European Innovation Council (EIC), this financing includes a €5M investment from Heran Partners and the Dutch-based Borski Fund.
“Thirona has demonstrated exceptional promise in the field of medical imaging,” says Katleen Vandersmissen of HERAN Partners. We are thrilled to help them in their endeavor to use artificial intelligence to transform healthcare.
According to Simone Brummelhuis of the Borski Fund, Thirona will be given resources to increase its market presence thanks to the money. Brummelhuis continues, “Thirona has established co-innovation alliances with top medical organizations and emerged as a leader in the MedTech space for lung image analysis.”
The Borski Fund aims to close this funding gap for female entrepreneurs who want a positive effect. This is done to support diversity in investing.
“Medical image analysis powered by AI”
Scientist Eva van Rikxoort launched Thirona BV in 2014, an AI business specializing in finely tuned retinal and lung imaging image processing. It provides knowledge-based services to firms in the medtech, pharmaceutical, and CRO (Contract Research Organization) sectors.
By analyzing medical pictures, Thirona believes its technology may dramatically increase the accuracy and efficiency of bronchoscopic and surgical lung treatments, including robotic procedures, making them simpler and less intrusive.
The Dutch company’s platform for lung quantification, LungQ, incorporates a potent and effective collection of AI-based algorithms. These algorithms provide the best analytical skills since they were trained on various disease-specific datasets.
The firm claims to be a recognized specialist in sophisticated image analysis, with over 15 million photographs analyzed.
LungQ is a scalable AI platform that offers reliable and repeatable outcomes, making it appropriate for extensive multi-site clinical trials and exploratory research investigations.
Thirona collaborates with medical organizations and research centers to promote precision medicine to treat individualized lung diseases.
Utilization of capital
Thirona claims it will put the money to use to hasten the implementation of its “breakthrough” medical discoveries.
“We are very pleased with the confidence our investors have shown in our vision and capabilities,” says founder Eva van Rikxoort. With the support of this financing, we will be able to keep expanding the capabilities of AI-powered imaging and enhance individualized care for lung patients all around the globe.
Thirona’s CTO, Rita Priori, continues, “The future of healthcare is changing, and we are at the forefront of this transition, setting the standard in our industry. We are well-positioned to substantially influence patient care and the medical sector with the help of investors.
